Fig. 1.
Fig. 1. Favorable dosimetry in a patient with AML in PR (unique patient number 664). / Biodistribution of 1 mg 188Re-labeled anti-CD66 monoclonal antibody after 40 hours, in anteroposterior and posteroanterior projection.

Favorable dosimetry in a patient with AML in PR (unique patient number 664).

Biodistribution of 1 mg 188Re-labeled anti-CD66 monoclonal antibody after 40 hours, in anteroposterior and posteroanterior projection.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal